GREENWICH LIFESCIENCES INC (GLSI)
US3968791083 - Common Stock
Overall GLSI gets a fundamental rating of 2 out of 10. We evaluated GLSI against 564 industry peers in the Biotechnology industry. GLSI has a great financial health rating, but its profitability evaluates not so good. GLSI has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
GLSI had negative earnings in the past year.
In the past year GLSI has reported a negative cash flow from operations.
GLSI had negative earnings in each of the past 5 years.
In the past 5 years GLSI always reported negative operating cash flow.
1.2 Ratios
GLSI's Return On Assets of -180.18% is on the low side compared to the rest of the industry. GLSI is outperformed by 88.69% of its industry peers.
With a Return On Equity value of -210.64%, GLSI is not doing good in the industry: 69.30% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -180.18% | ||
| ROE | -210.64% | ||
| ROIC | N/A |
ROA(3y)-67.33%
ROA(5y)-2328.36%
ROE(3y)-69.67%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for GLSI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, GLSI has about the same amount of shares outstanding.
GLSI has more shares outstanding than it did 5 years ago.
GLSI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 101.51 indicates that GLSI is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 101.51, GLSI belongs to the best of the industry, outperforming 99.46% of the companies in the same industry.
There is no outstanding debt for GLSI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 101.51 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 6.91 indicates that GLSI has no problem at all paying its short term obligations.
The Current ratio of GLSI (6.91) is better than 66.97% of its industry peers.
A Quick Ratio of 6.91 indicates that GLSI has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.91, GLSI is in the better half of the industry, outperforming 67.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.91 | ||
| Quick Ratio | 6.91 |
3. Growth
3.1 Past
GLSI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.24%.
EPS 1Y (TTM)-14.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.87%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, GLSI will show a decrease in Earnings Per Share. The EPS will decrease by -9.81% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19.12%
EPS Next 2Y-9.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for GLSI. In the last year negative earnings were reported.
Also next year GLSI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
GLSI's earnings are expected to decrease with -9.81% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.81%
EPS Next 3YN/A
5. Dividend
5.1 Amount
GLSI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GREENWICH LIFESCIENCES INC
NASDAQ:GLSI (1/3/2025, 8:00:01 PM)
After market: 13.3386 +0.46 (+3.56%)12.88
+1.14 (+9.71%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners7.92%
Inst Owner Change13.49%
Ins Owners54.93%
Ins Owner Change0.19%
Market Cap169.24M
Analysts82.86
Price Target38.76 (200.93%)
Short Float %8.96%
Short Ratio18.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.3%
Min EPS beat(2)1.96%
Max EPS beat(2)6.63%
EPS beat(4)3
Avg EPS beat(4)3.13%
Min EPS beat(4)-2.94%
Max EPS beat(4)6.86%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-23.53%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 33.97 | ||
| P/tB | 33.98 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0
BVpS0.38
TBVpS0.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -180.18% | ||
| ROE | -210.64% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-67.33%
ROA(5y)-2328.36%
ROE(3y)-69.67%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.91 | ||
| Quick Ratio | 6.91 | ||
| Altman-Z | 101.51 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.87%
EPS Next Y-19.12%
EPS Next 2Y-9.81%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.4%
OCF growth 3YN/A
OCF growth 5YN/A